Wasatch Advisors LP Buys 36,708 Shares of Dyne Therapeutics, Inc. $DYN

Wasatch Advisors LP boosted its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 9.0% in the 1st quarter, Holdings Channel reports. The institutional investor owned 443,668 shares of the company’s stock after buying an additional 36,708 shares during the quarter. Wasatch Advisors LP’s holdings in Dyne Therapeutics were worth $8,044,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. AQR Capital Management LLC bought a new stake in shares of Dyne Therapeutics in the 1st quarter worth about $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Dyne Therapeutics by 5.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock worth $597,000 after purchasing an additional 2,886 shares during the period. Goldman Sachs Group Inc. grew its holdings in Dyne Therapeutics by 58.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock valued at $10,407,000 after purchasing an additional 366,183 shares during the last quarter. Caxton Associates LLP bought a new position in Dyne Therapeutics during the 1st quarter valued at about $157,000. Finally, Creative Planning raised its position in Dyne Therapeutics by 23.8% in the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock worth $138,000 after purchasing an additional 2,797 shares during the period. Institutional investors own 96.68% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on DYN. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Chardan Capital reiterated a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a report on Monday, March 9th. Morgan Stanley decreased their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th. Finally, Sanford C. Bernstein upped their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.17.

Dyne Therapeutics Trading Up 1.6%

Shares of DYN opened at $20.94 on Friday. The firm has a market capitalization of $3.46 billion, a price-to-earnings ratio of -6.50 and a beta of 1.09. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. Dyne Therapeutics, Inc. has a 1-year low of $8.06 and a 1-year high of $25.00. The company has a 50-day moving average of $18.45 and a 200 day moving average of $18.11.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the prior year, the company earned ($1.05) earnings per share. On average, research analysts expect that Dyne Therapeutics, Inc. will post -3 EPS for the current year.

Insider Transactions at Dyne Therapeutics

In related news, insider Douglas Kerr sold 1,564 shares of the stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total value of $28,715.04. Following the transaction, the insider owned 170,042 shares of the company’s stock, valued at $3,121,971.12. This represents a 0.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Erick Lucera sold 2,362 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.37, for a total value of $48,113.94. Following the completion of the transaction, the chief financial officer directly owned 121,563 shares in the company, valued at approximately $2,476,238.31. This trade represents a 1.91% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have bought 9,000 shares of company stock worth $156,800 and have sold 1,829,584 shares worth $35,509,357. Company insiders own 9.46% of the company’s stock.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.